Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial - The
5
$ 14.99
In stock
(483)
Product Description
Endocrine therapy in metastatic breast cancer-more than just CDK4/6 inhibitors
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial - The
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial - ScienceDirect
Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment
Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing - Ranghiero - Cytopathology - Wiley Online Library
Cancers, Free Full-Text
Is the Way to Tackle ESR1-driven Resistance in Metastatic Breast Cancer to Monitor ctDNA?
ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges
Full article: The evolution of cyclin dependent kinase inhibitors in the treatment of cancer
